PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12800980-2	2003	Dexamethasone (DXM) treatment of PHA-stimulated lymphocytes induced a decrease in CDK2 mRNA expression without any change in mRNA stability.	Dexamethasone	0-13	cyclin dependent kinase 2	Homo sapiens	82-86	
12800980-2	2003	Dexamethasone (DXM) treatment of PHA-stimulated lymphocytes induced a decrease in CDK2 mRNA expression without any change in mRNA stability.	Dexamethasone	15-18	cyclin dependent kinase 2	Homo sapiens	82-86	
9275052-7	1997	By contrast, differences in the activity of cyclin E-CDK2 complexes were found, with a profound decrease in the extracts of cells growth arrested by dexamethasone.	Dexamethasone	149-162	cyclin dependent kinase 2	Homo sapiens	53-57	
11295047-2	2001	A block of cell cycle checkpoint by dexamethasone and genistein correlates with a selective induction of cyclin-dependent kinase (Cdk) inhibitor p21WAF1/CIP1 in a tumor suppressor p53-independent manner and abolishment of Cdk2 phosphorylation.	Dexamethasone	36-49	cyclin dependent kinase 2	Homo sapiens	222-226	
10867026-5	2000	Administration of dexamethasone at this, but not earlier stages, results in reduction of cyclin A and CDK2 levels with a parallel decrease in the associated kinase activity, dissociation of cyclin A-CDK2 from the E2F4-p130 complexes, and inhibition of G(1)/S transition.	Dexamethasone	18-31	cyclin dependent kinase 2	Homo sapiens	102-106	
10867026-5	2000	Administration of dexamethasone at this, but not earlier stages, results in reduction of cyclin A and CDK2 levels with a parallel decrease in the associated kinase activity, dissociation of cyclin A-CDK2 from the E2F4-p130 complexes, and inhibition of G(1)/S transition.	Dexamethasone	18-31	cyclin dependent kinase 2	Homo sapiens	199-203	
10551775-5	1999	Within 11 h of DEX treatment, this was accompanied by an accumulation of cells in the G1 phase of the cell cycle with a corresponding decreased proportion of cells in the S phase and decreased CDK2 activity.	Dexamethasone	15-18	cyclin dependent kinase 2	Homo sapiens	193-197	
12204894-5	2002	Using Western blot analysis and in vitro kinase assays, we found that dexamethasone results in decreased activity of CDK2 and 4, decreased levels of cyclin D, E2F, and Myc, and increased levels of the CDK inhibitor p21(Cip1).	Dexamethasone	70-83	cyclin dependent kinase 2	Homo sapiens	117-127	
10392902-8	1999	In addition, CDK2 kinase activity was decreased in DXM-treated cells: we suggest that p27Kip1 might participate in inhibiting its catalytic activity.	Dexamethasone	51-54	cyclin dependent kinase 2	Homo sapiens	13-17	
9271412-3	1997	We found that delaying the expression of Ras(Asn17) until late in the G1 phase by introducing dexamethasone 3 h after the addition of epidermal growth factor (EGF) abolished the downregulation of the p27kip1 cyclin-dependent kinase (CDK) inhibitor which normally occurred during this period, with resultant suppression of cyclin Ds/CDK4 and cyclin E/CDK2 and G1 arrest.	Dexamethasone	94-107	cyclin dependent kinase 2	Homo sapiens	350-354	
19428934-6	2009	We further found that indomethacin, celecoxib and dexamethasone increased the mRNA and protein expressions of p27(kip1) and decreased those of cyclin D2 and p-cdk2 in hOBs.	Dexamethasone	50-63	cyclin dependent kinase 2	Homo sapiens	159-163